Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Metabolon\u202f","sponsor":"BioFINDER","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Metabolon Partners with the Swedish BioFINDER 2 Study to Develop Biomarkers and Increase Insight into Alzheimer's and other Dementia Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Metabolon 

    Menu

    Metabolon 

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Metabolon 

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Metabolon Partners with the Swedish BioFINDER 2 Study to Develop Biomarkers and Increase Insight into Alzheimer's and other Dementia Diseases

              Details:

              The partnership aims to develop novel metabolomic biomarkers, assist in the development of new pathology-based disease classifications, and investigate underlying disease mechanisms of dementia to help discover new relevant drug targets.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: BioFINDER

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership September 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY